Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4604)	9/4/2001 5:50:05 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

really a tough trade. it was the first op that I thought of this morning. checked it at the open, and got scared off of the short. considered actually buying it. the short still would have paid handsomely, despite the awful open. but..... one of those days where you end up happy that you did nothing...... confusion from others arriving in your air space first. so....... I've waited as long as is reasonable. I need to add memory to this compie (J.D., that's what has stopped me from using the new CS platform..... thanks for your comments) and access a greater variety of ECNs. I presume that one could have done better than 13, pre-market?? (was anyone watching?)

To: Biomaven who wrote (4604)	9/4/2001 7:07:14 PM
From: rkrw	Read Replies (1) \| Respond to of 52153

Does the JNJ coated stent trivialize agix lead drug? Quarterly Highlights: * On May 21, 2001, AtheroGenics announced encouraging preliminary results of a Phase II clinical trial of AGI-1067, an oral agent for the treatment of restenosis after angioplasty. An analysis of the results indicated that six months after angioplasty, the blood vessels of patients who received AGI-1067 had greater luminal diameters of their coronary arteries compared to those receiving placebo. This improvement showed a statistically significant dose response. At the highest dose of AGI-1067, the increase in the size of the target blood vessel was similar to that achieved with probucol, the active control drug in CART-1, which has been shown in previous clinical studies to significantly reduce restenosis rates following angioplasty. A full analysis of the safety and efficacy data is underway, and expected to be announced later this year at a major medical conference.